Profitability
This table compares 374Water and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
374Water | -2,093.18% | -119.57% | -98.25% |
374Water Competitors | -97.39% | -458.26% | -3.72% |
Earnings and Valuation
This table compares 374Water and its competitors gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
374Water | $440,000.00 | -$12.43 million | -2.05 |
374Water Competitors | $3.57 billion | $273.35 million | 30.24 |
374Water’s competitors have higher revenue and earnings than 374Water. 374Water is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
Volatility & Risk
374Water has a beta of -0.22, suggesting that its stock price is 122% less volatile than the S&P 500. Comparatively, 374Water’s competitors have a beta of 0.63, suggesting that their average stock price is 37% less volatile than the S&P 500.
Summary
374Water competitors beat 374Water on 7 of the 9 factors compared.
About 374Water
374Water Inc. provides a technology that transforms wet wastes into recoverable resources in the United States. The company transforms wet wastes, including sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals. It offers AirSCWO systems, a waste stream treatment system based on supercritical water oxidation that are used to treat various hazardous and non-hazardous waste streams. It serves Industrial, agricultural, defense, oil and gas, waste management, sanitation project, environmental remediation and compliance, and municipal markets. 374Water Inc. is based in Durham, North Carolina.
Receive News & Ratings for 374Water Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 374Water and related companies with MarketBeat.com's FREE daily email newsletter.